Cardiologist
St. Michael's Hospital
University of Toronto
Toronto, Ontario, Canada
Dr. Kim Connelly is a Cardiologist and Scientist who is both nationally recognized as an expert in echocardiography, cardiovascular MRI and the impact of diabetes upon cardiac function and ventricular remodeling. Dr. Connelly runs a basic research laboratory at the Keenan Research Centre at St. Michael’s Hospital where he focuses upon basic mechanisms of disease – primarily around the role of pathological extracellular matrix accumulation with a focus upon translating discoveries into therapies in humans.
He has an H-index of 70 and i10-index of 232 (Google Scholar), and his work has been cited >16,704 times with publications in journals such as the NEJM, Circulation, Journal of the American College of Cardiology, Circulation Research, Diabetes, Cell Metabolism and Lancet Endocrinology and Diabetes. His work is diverse covering clinical guidelines statements, clinical trials, and preclinical studies along the themes of ventricular remodeling, diabetes, magnetic resonance imaging and echocardiography. He is a member of the editorial board of various journals such as The Canadian Journal of Cardiology and Cardiovascular Diabetology. He has received funding from the Heart and Stroke Foundation Canada, CIHR, Canadian Foundation of Innovation, Ministry of Ontario and industry sources, totally >$5.4 million as principal investigator. As a co-investigator, he has been part of >$23 million in funding, from the Ministry of Ontario, HSF, CIHR, CFI, and industry sources.
Dr. Connelly has been recognised for his contributions to science by being awarded a HSF clinician scientist award, a CIHR New Investigator Award, an Early Researcher Award from the Ministry of Ontario, the SC Verma award and the Insulin 100 emerging leader award to celebrate 100 years since the discovery of insulin at University of Toronto, as well as Canadian Cardiovascular Congress YIA 2012. He is past chair of the Canadian Cardiovascular guideline and was chair of the macrovascular complication section for Diabetes Canada CPG 2018.
Disclosure(s): Abbott Canada: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Boehringer Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Fibrocor: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); GSK: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Merck: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing); Qanatpharma: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); Sanofi: Consultant (Ongoing), Speaker/Honoraria (Ongoing); Servier: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (Ongoing)
AS01 - Evolution of GLP-1 and GIP/GLP1 Therapies: From Trial Evidence to Clinical Practice
Thursday, November 27, 2025
13:00 - 14:15 Toronto